T cell-specific in vivo transduction with preclinical candidate KLN-1010 generates BCMA directed CAR T cells with potent anti-multiple myeloma activity
用户xH737f_pTw7c
1个月前
69
10
已关闭
DOI:
文献链接:
其他信息:
ET Beura, HJ Latimer, D Wong, J Obrigewitch…
Cancer …, 2024
aacrjournals.org
Abstract Introduction: Multiple Myeloma (MM) is the second most diagnosed hematologic malignancy and remains an incurable disease. KLN-1010 is a novel treatment for MM currently in preclinical development that uses our iGPSTM platform, an envelope-modified lentiviral vector particle engineered for specific and efficient in vivo gene delivery, to transduce T cells. T cells modified in vivo by KLN-1010 express a fully human anti-BCMA CAR following a single IV injection without the need for additional treatments or conditioning …
